Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study will test the safety of an HPV DNA vaccine after it is injected into your muscle
using an electroporation device (TriGridTM Delivery System made by Ichor Medical Systems),
and will test the ability of the vaccine to help your body's immune system to recognize
HPV-infected and associated cancer cells. In addition to giving the vaccine using an
electroporation device, we are giving the vaccine in combination with an immunomodulatory
agent to further enhance immune responses against HPV-infected and associated cancer cells.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Ichor Medical Systems Incorporated National Institute of Dental and Craniofacial Research (NIDCR)